ADVFN - Advanced Financial Network.
HOME» NYSE » G » GSK Stock Price » GSK Stock News

Glaxosmithkline Share News

 Glaxosmithkline Stock Price
GSK Stock Price
 Glaxosmithkline Stock Chart
GSK Stock Chart
 Glaxosmithkline Stock News
GSK Stock News
 Glaxosmithkline Company Information
GSK Company Information
 Glaxosmithkline Stock Trades
GSK Stock Trades

AstraZeneca Needs To Replenish Drug Pipeline - Chairman

By Marta Falconi ZURICH--AstraZeneca PLC (AZN) aims to replenish its thin pipeline of new drugs through external collaborations and by buying drugs in late stages of development from other drugmakers, Chairman Leif Johansson said in an interview Tuesday. His comments come after the company announced it appointed former Roche head of pharma, Pascal Soriot, as chief executive, to succeed David Brennan, who earlier this year retired abruptly amid shareholder dissatisfaction with the company's performance. "There's a number of medicines going off patent," Mr. Johansson said. "We need to replenish them." The U.K.'s No. 2 drug maker by sales, after GlaxoSmithKline PLC (GSK), has suffered a number of expensive drug-development failures, and shown a poor track record in bringing new medicines to market, analysts say. Some of AstraZeneca's biggest drugs are facing, or will soon face, competition from low-cost generics. Mr. Johansson also said that while the pharmaceutical sector is facing challenges, there are also opportunities, such as the possibility of buying buy late-stage drugs, emerging markets and advances in science, including genome technology, which he touted as a way to learn how the human body works and possibly help find new drugs. Write to Marta Falconi at Subscribe to WSJ:

Stock News for Glaxosmithkline (GSK)
12/05/201607:30:00Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma...
12/02/201613:20:43Report of Foreign Issuer (6-k)
12/02/201611:07:11Report of Foreign Issuer (6-k)
12/02/201609:56:00GlaxoSmithKline Files for Approval of Three Drugs
12/02/201609:15:00GSK Files Regulatory Submission in European Union for Once-Daily...
12/02/201607:11:09Report of Foreign Issuer (6-k)
12/02/201602:00:00Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use i...
12/01/201609:48:40Report of Foreign Issuer (6-k)
11/30/201613:37:12Report of Foreign Issuer (6-k)
11/25/201610:29:04Report of Foreign Issuer (6-k)
11/25/201609:10:00GlaxoSmithKline Sumbits Application For Shingles Treatment Shingrix
11/25/201608:00:26Report of Foreign Issuer (6-k)
11/24/201606:46:00GlaxoSmithKline Starts Phase III Studies with Daprodustat
11/23/201608:08:14Report of Foreign Issuer (6-k)
11/23/201602:56:00GlaxoSmithKline: Mepolizumab Meets Major Targets in Phase III...
11/21/201608:28:00GSK receives FDA approval for expanded indication for FluLaval®...
11/21/201607:00:00GSK files regulatory submission in US for once-daily closed triple...
11/21/201606:19:12Report of Foreign Issuer (6-k)
11/21/201602:00:00GSK Files Regulatory Submission in US for Once-Daily Closed Triple...
11/18/201612:16:43Report of Foreign Issuer (6-k)

Glaxosmithkline and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations